Overview
RTW Biotech Opportunities (formerly RTW Venture Fund) seeks to achieve positive absolute performance and superior long-term capital appreciation through forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and extend patient life.
You can access the company’s website here
You can view our interviews with the company’s Fund Managers below:
20th January 2023: Stephanie Sirota – Weekly Report
Fundamentals
Price
Research History
-
20 Jan 2023 1 min read
Interview with Stephanie Sirota from RTW Venture Fund
In this week’s show, James Carthew spoke to Stephanie Sirota from RTW Venture Fund. If you were looking for the first part of QuotedData’s show, focused on the roundup of the week’s news, click here. If there is a guest speaker you’d particularly like to hear from, please email us on [email protected]. Additionally, if you would […]
-
05 Jan 2023 9 min read
QuotedData’s Investment Companies Roundup – January 2023
December 2022 Monthly roundup | Investment companies Winners and losers in December 2022 The Financials sector only has two constituents, one of these – Trian Investors 1 – has seen its discount narrow since it promised to return cash to investors by next June, and it has also benefited from underlying NAV appreciation. Last month’s […]
-
07 Dec 2022 8 min read
QuotedData’s Investment Companies Roundup – December 2022
Investment Companies Monthly Roundup Kindly sponsored by abrdn December 2022 Monthly | Investment companies Winners and losers in November 2022 As discussed in this month’s economic and political roundup, lower US inflation triggered a fall in the US dollar and drove equity markets higher over November. The big surprise was the resurgence of Chinese markets […]
-
13 Oct 2022 14 min read
QuotedData’s Investment Companies Quarterly Review – Third Quarter 2022
Third quarter of 2022 Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Piling on the misery In the face of rising inflation, exacerbated by the war in Ukraine, central bankers have condemned for their relative inaction. However, in the third quarter of 2022, they stepped up a gear. Last month’s economic and political roundup […]
-
06 Oct 2022 111 min read
QuotedData’s Economic and Political Monthly Roundup October 2022
Economic and Political Monthly Roundup Investment companies | Monthly | October 2022 A collation of recent insights on markets and economies taken from the comments made by chairs and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to […]
-
11 Jun 2021 1 min read
Interview with Stephanie Sirota of RTW Ventures
In this week’s show, James Carthew talked to Stephanie Sirota of RTW Ventures. Watch it again here If you were looking for QuotedData’s roundup of the week’s news, this is now in the news section – just click here. If there is a guest speaker you’d particularly like to hear from, please email us – [email protected]. The […]
-
10 Mar 2020 7 min read
QuotedData’s Investment Companies Roundup – March 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Table of contents New research In this issue Performance data Discounts and premiums Money in and out Major news stories Income Events Guide New research Here is a list of research we published over February: An initiation note on Montanaro UK Smaller Companies Trust (MTU) […]
-
07 Feb 2020 7 min read
QuotedData’s Investment Companies Roundup – February 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford Table of contents New research In this issue Performance data Discounts and premiums Money in and out Major news stories Income Events Guide New research Here is a list of research we published over January: An annual overview note on Shires Income (SHRS) “Shires Income (SHRS) will […]
-
24 Jan 2020 20 min read
QuotedData’s Investment Companies Annual Review – 2019
In this issue The sector at the end of 2019 Performance data Performance by sector and fund Money in and out of the sector Money in and out of existing funds Money coming into existing funds Money going out of existing funds Liquidations, de-listings and trading cancellations Significant rating changes Major news stories Outlook for […]
-
10 Jan 2020 5 min read
QuotedData’s investment companies roundup – January 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford Table of contents New research In this issue Performance data Discounts and premiums Money in and out Income Events New research Here is a list of research we published over December: An update note on BlackRock Throgmorton (THRG) “BlackRock Throgmorton continues to lead its peer group in […]
News
-
15 Nov 2024 1 min read
Application for RTW Biotech Opportunities’ CORXEL’s Aficamten accepted by Chinese regulator
CORXEL Pharmaceuticals, a portfolio company of RTW Biotech Opportunities (RTW), has had a new drug application accepted by China’s National Medical Products Administration (NMPA). The application acceptance is for the use of Aficamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM). RTW describes Aficamten as “an investigational, next-in-class selective small molecule cardiac myosin inhibitor”. The […]
-
03 Oct 2024 1 min read
RTW backs obesity drug firm
The manager of RTW Biotech Opportunities has led a $400m Series A financing round for a new portfolio company, Kailera Therapeutics. The announcement does not disclose how much of that came from the listed fund. RTW Investments co-led the Series A with Atlas Venture and Bain Capital Life Sciences, with participation from Lyra Capital. The […]
-
02 Oct 2024 1 min read
QuotedData’s morning briefing 2 October 2024 – RTW
In QuotedData’s morning briefing 2 October 2024: RTW Biotech Opportunities (RTW) announced a new investment in Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumours. RTW, alongside other investment vehicles managed by RTW Investments (the investment manager), co-led Aktis’s Series […]
-
27 Sep 2024 2 min read
QuotedData’s morning briefing 27 September 2024 – RTW, INPP, ASLI
In QuotedData’s morning briefing 27 September 2024: BioAge Labs, Inc., a portfolio company of RTW Biotech Opportunities (RTW), has completed a US$198m initial public offering (IPO) and is now trading on the Nasdaq Global Select Market under the ticker: BIOA. The company raised the US$198m by offering 11,000,000 shares at US$18.00 per share and, as […]
-
26 Sep 2024 2 min read
QuotedData’s morning briefing 26 September 2024 – RMII, CGL, RNEW, RTW, LABS, PSDL
In QuotedData’s morning briefing 26 September 2024: RM Infrastructure Income (RMII) says its latest tender was taken up in full – 19,738,338 shares will be bought back at the tender price of 88.59p (equivalent to the NAV as at 30 August 2024). The money should be in your account on Monday. Iona Star LP, the […]
-
13 Sep 2024 4 min read
QuotedData’s morning briefing 13 September 2024 – RTW, MNTN, BSRT, JEMA, PCT, TPOU
In QuotedData’s morning briefing 13 September 2024: RTW Biotech Opportunities (RTW) has announced its interim results for the six months ended 30 June 2024, during which its NAV was up 3.0% and its share price was up 10.1%. In comparison, RTW says that its comparator indices – Russell 2000 Biotech and Nasdaq Biotech were up […]
-
06 Aug 2024 1 min read
RTW backs Jade Biosciences
RTW Biotech Opportunities (RTW) has announced an investment in new portfolio company, Jade Biosciences. RTW, alongside other investment vehicles managed by RTW Investments LP, participated in Jade’s financing round that raised $80m for its launch. The funding will be used to support Jade’s plans to develop targeted therapies for indications with high unmet need across […]
-
19 Jul 2024 4 min read
Time to inject some healthcare into your portfolio?
The healthcare and biotechnology sector has some natural tailwinds: ageing populations, rising emerging market wealth, innovation and rising healthcare utilisation. However, while pharmaceutical companies have been stable, biotechnology has been hit by poor sentiment and rising interest rates. Nevertheless, there are signs of recovery. The sector is diverse. Funds such as Polar Capital Global Healthcare […]
-
02 Jul 2024 1 min read
QuotedData’s morning briefing 2 July 2024 – JGGI, RTW, IHR
In QuotedData’s morning briefing 2 July 2024: JPMorgan Global Growth & Income (JGGI) announced that it intends to pay dividends totalling 22.80 pence per share (5.70 pence per share per quarter) in relation to its financial year commencing 1st July 2024. This is in line with its policy of paying out 4.0% of the company’s […]
-
13 Jun 2024 2 min read
QuotedData’s morning briefing 13 June 2024 – RTW, FAIR, FSFL, DGI9
In QuotedData’s morning briefing 13 June 2024: RTW Biotech Opportunities (RTW) says its largest (13.4% of the portfolio) holding, Avidity Biosciences Inc. has announced positive initial data from its Phase 1/2 trial of AOC 1020, an investigational therapy that targets DUX4, the root cause of facioscapulohumeral muscular dystrophy (FSHD). AOC 1020 demonstrated unprecedented and consistent […]
-
11 Jun 2024 1 min read
QuotedData’s morning briefing 11 June 2024 – USF, VNH, RTW, SMIF, PCFT
In QuotedData’s morning briefing 11 June 2024: The US Solar Fund (USF) will purchase in aggregate 24,358,974 shares under its previously announced tender offer at a price of $0.764 per share. This is the maximum number of shares to be acquired, representing approximately 7.33% ($19m) of the issued share capital of the company. VietNam Holding […]
-
15 May 2024 2 min read
QuotedData’s morning briefing 15 May – RTW, GIF, NESF, IHR
In QuotedData’s morning briefing 15 May 2024: RTW Biotech Opportunities (RTW) portfolio company, Lycia Therapeutics, announced the completion of a $106.6m Series C financing round. The company, alongside other investment vehicles managed by RTW Investments LP, participated in the financing round with other life science investment firms. Gulf Investment Fund (GIF) announced that it has […]
-
03 May 2024 1 min read
QuotedData’s weekly news show 3rd May 2024
Thank you to everyone that listened in today, whether you watched the Zoom live or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • Aberforth Split Level Income (0:33) • Chrysalis (6:24) Andrew McHattie highlighted a number of funds that were looking unusually cheap or expensive (10:24). This week’s interview […]
-
28 Mar 2024 3 min read
RTW Biotech had a great 2023
RTW Biotech Opportunities had a great year in 2023, returning 23.5% in NAV terms and 16.0% in share price terms, both well ahead of the 10.6% return posted by the Russell 2000 Biotech index and even further ahead of the 3.7% return generated by the Nasdaq Biotech Index. Some highligts: During the year ended 31 […]
-
09 Feb 2024 2 min read
QuotedData’s morning briefing 9 February 2024 – INOV, RTW, ADIG
In QuotedData’s morning briefing 9 February 2024: Schroders Capital Global Innovation Trust (INOV) has invested US$1.6m in Neurona Therapeutics through its Series E financing round, which raised US$120m. The fundraising was co-led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors including The Column Group, Passaic Capital Management, Lyfe […]
-
30 Jan 2024 1 min read
QuotedData’s morning briefing 30 January 2024 – UKW, RTW, IHR
In QuotedData’s morning briefing 30 January 2024: Greencoat UK Wind (UKW) announced the appointment of Abigail Rotheroe as a non-executive director of the company. Her appointment will be effective from 1 March 2024. Abigail is a CFA Charterholder and brings over 20 years’ experience in the investment industry. She is the former investment director of […]
-
22 Jan 2024 1 min read
RTW comes closer to acquiring Arix’s assets
RTW Biotech Opportunities (RTW) has provided an update on Arix and its capital allocation plan. RTW has now completed the previously announced $57.1m acquisition of a 25.5% stake in Arix. RTW intends to utilise its stake to vote in favour of the “Arix scheme” at Arix’s forthcoming AGM. RTW intends to leverage its position in […]
-
13 Nov 2023 2 min read
QuotedData’s morning briefing 13 November 2023
In QuotedData’s morning briefing 13 November 2023: Marwyn Value Investors (MVI) has announced that it has made a £7.8m investment into Zegona Communications, participating in a total equity placing of £262m. This equity raise was made as part of Zegona’s acquisition of Vodafone Holdings Europe, S.L.U. (“Vodafone Spain”) for €5.0bn, funded through a combination of […]
-
03 Nov 2023 1 min read
QuotedData’s weekly news update 3rd November 2023
Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • RTW / Arix (0:47) Andrew McHattie picked up on the positive reaction from markets in response to the Bank of England holding interest rates, […]
-
01 Nov 2023 3 min read
RTW Biotech Opportunities to acquire Arix Bioscience
RTW Biotech Opportunities (RTW) has announced that it will acquire Arix Bioscience. The transaction is expected to deliver RTW with an expected pro-forma net asset value of approximately $550 million, an increase of 63% The deal will enhance RTW’s profile, provide increased liquidity potential, a more efficient cost base, and a re-rating opportunity. Arix shareholders […]
-
14 Sep 2023 2 min read
QuotedData’s morning briefing 14 September 2023 – CGL, SONG, RTW, FSFL, ASCI, BHMG, BCPT
Castelnau Group (CGL) announced the appointment of Richard Brown as non-executive director of the company and chief executive officer of Castelnau Group. A former investment banker, Richard has over 14 years of corporate finance experience. He has advised firms ranging from the largest FTSE 100 companies to private businesses, UK-focused as well as international. The […]
-
05 Sep 2023 1 min read
QuotedData’s morning briefing 5 September 2023 – CLDN, BOOK, RTW, HGT
In QuotedData’s morning briefing for 5 September: Caledonia Investments (CLDN) announced that it has agreed terms for the sale of its majority stake in Seven Investment Management , a vertically integrated retail wealth management business, to Ontario Teachers’ Pension Plan Board, a global investor with approximately C$250 billion in net assets. Caledonia is expected to […]
-
17 Jul 2023 2 min read
QuotedData’s morning briefing 17 July 2023
In QuotedData’s morning briefing 17 July 2023: Cordiant Digital Infrastructure (CORD) has announced that its portfolio company, Emitel S.A, has refinanced its senior loans, securing €353m in financing which matures in 2030. The new facility was 1.6 times oversubscribed, with a blended rate lower than the 2.9% of its current senior facilitates. The new loans […]
-
05 Jul 2023 1 min read
QuotedData’s morning briefing 5 July 2023
RTW Biotech Opportunities (RTW) provided an update on its intended use of proceeds from its holding in Prometheus Biosciences, Inc., following its acquisition by Merck. The sale resulted in total proceeds of $99.1 million on total invested capital of $8.4 million, representing a 11.8x multiple. RTW plans to split the proceeds across a series of […]
-
27 Jun 2023 2 min read
QuotedData’s morning briefing 27 June 2023
In QuotedData’s morning briefing 27 June 2023: RTW Venture Fund has changed its name to RTW Biotech Opportunities. The Guernsey registry has confirmed the name change, effective 22 June 2023. The ticker remains the same (RTW). Seed Innovation’s (SEED) results show [deep within the text] that its NAV fell from £20.461m to £16.032m, or 9.62p […]
-
14 Jun 2023 1 min read
QuotedData’s morning briefing 14 June 2023
RTW Venture Fund Limited (RTW) announced the unaudited update for the month of May, with NAV growing 1.9% to US$365.2m. Shares rose 2.5% over the same period, and the discount narrowed slightly to 26%. Sequoia Economic Infrastructure Income Fund (SEQI) provided a NAV and investments update for May with NAV growing around 66 basis points […]
-
09 May 2023 3 min read
QuotedData’s morning briefing 9 May 2023
RTW Venture Fund Limited (RTW) provided an update for one of its portfolio companies, Acelyrin which announced an up-sized $540 million initial public offering and admission to trade on the Nasdaq Global Market under ticker “SLRN”. Acelyrin is a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology. […]
-
02 May 2023 2 min read
RTW wraps up challenging year for BioTech
RTW Venture Fund (RTW) announced annual results for the year ended December 31 2022. NAV fell 10.2%, while shares were down -32% underperforming both of the company’s benchmarks with the Russell 2000 Biotech and Nasdaq Biotech indices down -31.3% and -10.9% respectively. The company’s discount fell to as low as 37% for the year although […]
-
26 Apr 2023 1 min read
QuotedData’s morning briefing 26 April 2023
RTW Venture Fund Limited announced that Abdera Therapeutics has completed its $142M Series A and Series B financing rounds in which it participated. Abdera is a privately held pre-clinical stage biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. The company is building a pipeline of potentially best-in-class therapies for […]
-
21 Apr 2023 1 min read
QuotedData’s weekly news show 21st April 2023
Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • HydrogenOne (1:04) • RTW Venture Fund (6:22) • Triple Point Social Housing REIT / Civitas Social Housing (8:01) This week’s interview was with Jean Roche […]
-
17 Apr 2023 1 min read
QuotedData’s morning briefing 17 April 2023
In QuotedData’s morning briefing for 17 April 2023: RTW Venture Fund (RTW) has announced that its largest holding, Prometheus Biosciences (equal to c14.8% of RTW’s NAV) has been acquired by Merck for $200 per share, a 75% premium to its prior closing price. This would value Prometheus at c.$10.8bn. Prometheus is a clinical-stage biotechnology company […]
-
31 Mar 2023 2 min read
Strong outperformance from RTW Venture aided by realisations
RTW Venture (RTW) has published its annual results for the year ended 31 December 2022, During the year, RTW’s NAV declined by -10.2% (from US$363.0m or US$1.71 per share to US$326.1m or US$1.54 per share) with the main detractor being the markdown in Ji Xing (c. -2.2% contribution), after the IPO was delayed due to […]
-
30 Mar 2023 2 min read
QuotedData’s morning briefing 30 March 2023
In QuotedData’s morning briefing 30 March 2023: RTW Venture Fund (RTW) was part of a consortium of funds managed by the same manager that participated in a $125m funding for Milestone Pharmaceuticals. Milestone is a publicly traded biopharmaceutical company, which is shepherding etripamil, its lead investigational product, through Phase 3 clinical trials for paroxysmal supraventricular […]
-
14 Mar 2023 2 min read
More SVB updates – fortunately not too serious
A number of funds made comments on the fallout from the collapse of Silicon Valley Bank and Signature – as far as we can tell, there is nothing earth-shattering here. HarbourVest may be worrst-affected. Although as the managers of Polar Capital Global Financials Trust suggest, this episode may not be quite over yet. NB Private […]
-
01 Mar 2023 1 min read
RTW funds Oricell Therapeutics
RTW Venture Fund, alongside other investment vehicles managed by its investment manager, co-led participation in Oricell Therapeutics’ $45m Series B-1 financing round together with Qatar Investment Authority, with participation from existing investors, including Qiming Venture Partners and C&D Emerging Industry Equity Investment. Oricell, which was founded in 2015, is a China-based innovative pharmaceutical company committed […]
-
14 Feb 2023 1 min read
QuotedData’s morning briefing 14 February 2023
In QuotedData’s morning briefing 14 February 2023: Regional REIT (RGL) says the vast majority (99%) of its office tenants have returned to the office, with a hybrid work pattern of three to four days in the office and one to two days at home the favoured combination. The company says its regional office portfolio, which comprises […]
-
09 Dec 2022 1 min read
QuotedData’s weekly news show 9th December 2022
Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • VPC Speciality Lending • RTW Venture • Syncona This week’s interview was with Stuart Widdowson from Odyssean Investment Trust – watch it again here.
-
4 min read
RTW gets boost from Prometheus trial success
RTW Venture Fund has drawn investors’ attention to positive data updates on two clinical trials of Prometheus Biosciences, Inc. (NASDAQ: RXDX), its third largest holding, representing about 7.5% of NAV. Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for […]
-
08 Dec 2022 1 min read
RTW Venture backs Apogee
RTW was a co-lead in a $149m Series B financing round for Apogee Therapeutics, LLC, a biotechnology company focused on immunological and inflammatory disorders. RTW Venture participated in the fundraise but we have not been not told what its contribution was. Proceeds from the financing will be used to support Apogee’s plans to advance its […]
-
16 Sep 2022 5 min read
QuotedData’s morning briefing 16 September 2022
In QuotedData’s morning briefing 16 September 2022: RTW Venture’s (RTW’s) portfolio company, Third Harmonic Bio Inc., has completed its initial public offering (IPO) and has listed on Nasdaq (ticker: THRD). The upsized issue raised US$185.3m by offering around 10.7m shares at US$17.00 per share. Third Harmonic Bio is a clinical-stage biotechnology company developing a first-in-class, […]
-
20 Jul 2022 2 min read
QuotedData’s morning briefing 20 July 2022
In QuotedData’s morning briefing 20 July 2022: The Renewables Infrastructure Group (TRIG) has exchanged contracts to acquire a further 2.4% equity interest in the Hornsea One offshore wind farm from Global Infrastructure Partners (from whom the company announced the acquisition of its original stake in March 2022). Upon completion of this incremental investment, TRIG will […]
-
06 Jul 2022 2 min read
QuotedData’s morning briefing 6 July 2022
In QuotedData’s morning briefing 6 July 2022: abrdn China (ACIC) has posted its interim results for the period from its change of mandate in October 2021 to 30 April 2022. It has been a testing period for most equity markets, but China has been particularly challenging and the trust’s NAV return was a dismal -21.5%. […]
-
14 Apr 2022 1 min read
RTW backing Lenz Therapeutics
RTW Venture Fund notes that LENZ Therapeutics has entered into an exclusive license agreement with Ji Xing Pharmaceuticals to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia (the loss of reading vision due to age) in Greater China. RTW Investments, LP (the investment manager) has invested $10m on […]
-
31 Mar 2022 1 min read
RTW Venture struggles in difficult year for biotech
2021 was a difficult year for small cap biotech and this shows in RTW Venture’s results. Over the course of the year, the NAV fell by 13% and the share price by 5%. That compares to a 1% return on the NASDAQ Biotech Index and a -27% return on the Russell 2000 Biotech Index (which […]
-
17 Feb 2022 1 min read
RTW makes two investments
RTW makes two investments: Magnolia Medical Technologies RTW says that Magnolia Medical Technologies has completed a $46m growth equity financing round. The company, alongside other investment vehicles of RTW Investments, LP, participated in the financing round together with other investors. Magnolia Medical is a privately held medical technology company that develops, manufactures, and markets innovative […]
-
27 Jan 2022 1 min read
RTW backs Kyverna
RTW Venture Fund has announced that it participated in an $85m Series B funding round for Kyverna Therapeutics, Inc. on 26 January. RTW invested alongside other investment vehicles of RTW Investments, LP (the investment manager) as well as other investors. Kyverna is a privately held cell therapy company engineering a new class of therapies for […]
-
10 Jan 2022 4 min read
QuotedData’s morning briefing 10 January 2022
In QuotedData’s morning briefing 10 January 2022: Following its decision to terminate its investment management arrangement with KKV Investment Management, Secured Income Fund (SSIF) is now a self managed AIFM. The company has entered into a consultancy agreement to secure the services of one of the individuals previously employed by KKVIM and who has the […]
-
13 Oct 2021 2 min read
QuotedData’s morning briefing 13 October 2021
In QuotedData’s morning briefing 13 October 2021: RTW Venture Fund (RTW) holding, CinCor Pharma has completed a $143m Series B financing round. RTW participated in the round alongside other investors. CIO, Roderick Wong, said: “We are delighted to support CinCor’s efforts to develop next-generation treatments for hypertension, a condition that affects a significant patient population […]
-
11 Oct 2021 2 min read
QuotedData’s morning briefing 11 October 2021
In QuotedData’s morning briefing 11 October 2021: VH Global Sustainable Energy Opportunities (GSEO) has completed its acquisition of the first 5MW solar photovoltaic site near Adelaide, South Australia. This is part of the first tranche consisting of two sites totalling 17MW as announced on 2 August 2021. Battery storage will be built and co-located on […]
-
10 Sep 2021 2 min read
QuotedData’s morning briefing 10 September 2021
In QuotedData’s morning briefing 10 September 2021: RTW Venture (RTW) has announced a new portfolio investment in Lycia Therapeutics, following its participation in the company’s US$70m series B financing round, the proceeds of which are intended to advance Lycia’s discovery pipeline of LYTAC degraders. Lycia is a privately held biotechnology company developing extracellular protein degradation […]
-
09 Sep 2021 2 min read
RTW Venture backs InBrace
RTW Venture backs InBrace – RTW Venture Fund, other investment vehicles of RTW Investments, and other investment firms participated in the $102m Series D funding round for InBrace on 08 September 2021. InBrace is a privately held medical technology company pioneering SmartwireTM, a behind-the-teeth teeth straightening approach. The company treats all types of orthodontic cases […]
-
17 Aug 2021 1 min read
QuotedData’s morning briefing 17 August 2021
In QuotedData’s morning briefing 17 August 2021: We noted yesterday that RTW Venture was conducting a quick fundraise. In the event, RTW issued 1,419,276 new shares. AEW UK REIT (AEWU) is managed by AEW UK Investment management LLP, a joint venture between AEW in Europe and Richard Tanner, Rachel McIsaac and Nick Winsley – investing through an […]
-
16 Aug 2021 2 min read
QuotedData’s morning briefing 16 August 2021
In QuotedData’s morning briefing 16 August 2021: NB Global Monthly Income (NBMI) has invested in a new 2nd lien senior secured loan from Parexel, which came to the market in July. The company helps pharmaceuticals manage and execute clinical trials. Following a 3-year turnaround plan under a new management team, NBMI believes it is well positioned to […]
-
06 Aug 2021 2 min read
QD view – do we love tech or not?
Our monthly roundup of news and views from the investment companies sector should be hitting your inboxes shortly. The macro roundup contains a long and detailed but fascinating look at the technology sector from Ben Rogoff, manager of Polar Capital Technology. He was writing in the trust’s annual report, which was published on 20 July. […]
-
27 Jul 2021 2 min read
RTW Venture backs Artios Pharma
RTW Venture backs Artios Pharma – RTW Venture says it participated in Artios Pharma’s $153m series C funding round. The oversubscribed financing was co-led by Omega Funds and TCG X. Additional investors include Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital. […]
-
14 Jul 2021 2 min read
QuotedData’s morning briefing 14 July 2021
In QuotedData’s morning briefing 14 July 2021: Apax Digital Fund, which is backed by Apax Global Alpha, is making an investment in Tide as part of a series C funding round. Tide, a business financial platform offering business accounts and related banking services, as well as a comprehensive set of integrated software solutions, is already a […]
-
28 Jun 2021 3 min read
QuotedData’s morning briefing 28 June 2021
In QuotedData’s morning briefing 28 June 2021 – RTW Venture (RTW), focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, noted the 24 June announcement by one of its portfolio companies, GH Research regarding its pricing of a $160m IPO and admission to trade on the Nasdaq global market under ticker ‘GHRS.’ GH Research is […]
-
16 Jun 2021 1 min read
QuotedData’s morning briefing 16 June 2021
In QuotedData’s morning briefing 16 June 2021 – RTW Venture (RTW) raised gross proceeds of $8.967m following the issue of ordinary shares at a price of $2.07. Further to its announcements on 28 May 2021, Ashoka India Equity (AIE) announced the results of its initial issue, with applications for 2.85m ordinary shares having been received. The shares will […]
-
15 Jun 2021 1 min read
RTW backs Umoja Biopharma
RTW backs Umoja Biopharma – Umoja Biopharma, Inc. has just completed a $210m Series B financing round. RTW Venture Fund participated in the financing round together with other investment firms, including other investment vehicles of RTW Investments, LP. Umoja is a US-based privately held oncology company. It is using a new approach to immunotherapy, reprogramming immune cells directly […]
-
26 May 2021 1 min read
RTW Venture backs NiKang Therapeutics Series C
RTW Venture backs NiKang Therapeutics Series C – NiKang Therapeutics, Inc announced on 26 May 2021 that it had completed a $200m Series C financing round. RTW Venture alongside other investment vehicles of RTW Investments, LP participated in the financing round. Investors in the Series C include Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital; syndicates of funds, […]
-
29 Apr 2021 1 min read
RTW Venture looking very healthy
RTW Venture looking very healthy – RTW Venture Fund has published its annual report for the year ended 31 December 2020. Over the year, its NAV increased by 54%. This makes it 88.5% NAV growth since IPO. The share price rose by 37% – the premium was perhaps too high at the start of the year. The […]
-
19 Apr 2021 1 min read
QuotedData’s morning briefing 19 April 2021
In QuotedData’s morning briefing 19 April 2021 – RTW Venture (RTW) made a note of the 15 April 2021 announcement by one of its portfolio companies, Biomea Fusion (Biomea), regarding its pricing of a $153m IPO and admission to trade on Nasdaq Global Market under ticker “BMEA”. Biomea is a preclinical-stage biopharmaceutical company focused on […]
-
30 Mar 2021 1 min read
RTW backs Pyxis Oncology
RTW backs Pyxis Oncology – RTW Venture Fund Limited has highlighted an announcement by Pyxis Oncology, Inc. On 30 March 2021 that company completed a $152 million Series B financing round, which was co-led by RTW Investments, LP. The company, alongside other investment vehicles of the Investment Manager, confirms that it participated in the financing round together with […]
-
10 Mar 2021 1 min read
RTW Venture participates in $114m and $36m financing rounds held by Ventyx Biosciences and Visus Therapeutics
RTW Venture Fund (RTW) made two investment announcements yesterday afternoon (9 March) – it participated in the $114m financing round held by Ventyx Biosciences as well as the $36m round held by Visus Therapeutics. The investments are in companies involved in molecule therapeutics and presbyopia-correcting eye drops RTW describes the companies as follows: “Ventyx is a privately-held clinical-stage biotechnology company […]
-
02 Mar 2021 2 min read
QuotedData’s morning briefing 2 March 2021
In QuotedData’s morning briefing 2 March 2021: Syncona (SYNC) notes that Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumours, announced it has filed a registration statement in relation to a proposed IPO. Syncona owns 44% of Achilles which it values at £72.4m. RTW Venture Fund (RTW) participated in a Series […]
-
26 Feb 2021 1 min read
RTW backs Artiva Biotherapeutics
RTW backs Artiva Biotherapeutics – RTW Venture Fund notes the announcement by Artiva Biotherapeutics of its completion of a $120m Series B financing round. RTW Venture Fund, alongside other of the investment manager’s vehicles, confirms that it participated in the financing round together with other investment firms. Roderick Wong, MD, managing partner and chief investment officer […]
-
08 Feb 2021 3 min read
QuotedData’s morning briefing 8 February 2021
In QuotedData’s morning briefing 8 February 2021 – Gabelli Value Plus+ (GVP) announced that it intends to convene a general meeting in July 2021 to consider a continuation vote resolution followed by a special resolution to place the company in members’ voluntary liquidation. GVP’s largest shareholder, Associated Capital Group, has irrevocably undertaken to abstain from […]
-
05 Feb 2021 1 min read
QuotedData’s weekly news show 5 February 2021
QuotedData’s weekly news show 5 February 2021 Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on Youtube. In this week’s show, James Carthew covered the week’s top stories: IPO boom – Next Energy Renewables, Digital 9 Infrastructure and Great Point Entertainment Round Hill Music update He […]
-
1 min read
Successful IPO for RTW Venture Fund’s Landos Biopharma
RTW Venture Fund has provided a brief update on portfolio company Landos Biopharma’s IPO. The IPO raised US$100 million by offering 6,250,000 shares at $16.00 per share, and Landos is now listed on the Nasdaq Global Market under ticker: LABP. Landos was one of the seed assets included in the Company’s portfolio at the time of […]
-
12 Jan 2021 1 min read
QuotedData’s morning briefing 12 January 2021
In QuotedData’s morning briefing 12 January 2021: UK Mortgages Limited is launching Hops Hill No.1, a securitisation of the portfolio of first ranking, buy-to-let mortgage loans originated by Keystone Property Finance. Keystone have been originating loans for UKML for the last two years with warehouse financing provided by NAB. The portfolio size reached almost £340m by 31st […]
-
07 Jan 2021 1 min read
RTW makes new investment in Biomea Fusion
RTW makes new investment in Biomea Fusion – RTW Venture Fund, alongside other investment vehicles of RTW Investments, LP – its investment manager – and other investment firms, has participated in a $56m Series A financing round for Biomea Fusion. Biomea is a US-based privately held precision oncology company dedicated to developing innovative medicines targeting specific […]
-
11 Dec 2020 1 min read
QuotedData’s weekly news show 11 December 2020
QuotedData’s weekly news show 11 December 2020 Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on Youtube. In this week’s show, James Carthew covered the week’s top stories: Keystone Jupiter US Smaller Companies RTW Venture Watch it again here We’ll be back on January 8th. This week’s […]
-
10 Dec 2020 1 min read
RTW’s Rocket takes off on good clinical data
RTW’s Rocket takes off on good clinical data – RTW Venture Fund notes positive data updates on four clinical trials of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This is the largest holding in RTW’s portfolio, representing about 30% of NAV. Rocket is advancing an integrated and sustainable pipeline of first-in-class genetic therapies that correct the root cause […]
-
08 Dec 2020 1 min read
RTW backs Nuance Pharma
RTW backs Nuance Pharma – RTW Venture Fund backed Nuance Pharma in its $181 million Series D financing round, which was co-led by the fund’s investment manager RTW Investments, LP. Nuance is a Chinese-based privately held fully integrated pharmaceutical company engaged in creating value through China’s specialty pharmaceutical markets, with an established focus on iron deficiency, […]
-
19 Oct 2020 2 min read
QuotedData’s morning briefing 19 October 2020
In QuotedData’s morning briefing 19 October 2020: The remaining conditions for UIL’s sale of Ascendant to Algonquin Power & Utilities Corp have been satisfied. UIL will get $37.6m. Ascendant owns 100% of Bermuda Electricity Light Company Limited, Bermuda’s sole electricity provider. JPMorgan Brazil has published a circular in relation to its planned wind up. Its shares will be […]
-
05 Oct 2020 1 min read
RTW Venture’s C4 Therapeutics IPO raises $182m
RTW Venture Fund (RTW), an investment company focused on identifying assets with high growth potential across the life sciences sector, noted the announcement by portfolio company, C4 Therapeutics, on 1 October of its pricing of a $182.4m IPO and admission to trading on the Nasdaq. ‘Robust pipeline in oncology’ C4T is a US‐based biotech company, described […]
-
02 Oct 2020 1 min read
Successful IPO for RTW Venture Fund’s Pulmonx Corporation
RTW Venture Fund’s portfolio company, Pulmonx Corporation, announced on 30 September 2020 the pricing of its US$190 million initial public offering (IPO) as well as its admission to trading on Nasdaq Global Market under the ticker: LUNG. Pulmonx is a medical device company that commercializes the Zephyr Valve System, which it says is the first […]
-
21 Sep 2020 2 min read
QuotedData’s morning briefing 21 September 2020
In QuotedData’s morning briefing 21 September 2020 – Crystal Amber (CRS) reported annual results to 30 June 2020. The UK smaller companies fund’s NAV fell by (55.4%) in total return terms. It was a better second half of the year, with CRS’ NAV increasing by 11.2% over the year-to-date to 30 June 2020. The main […]
-
12 Aug 2020 1 min read
QuotedData’s morning briefing 12 August 2020
In QuotedData’s morning briefing 12 August 2020: International Public Partnerships (INPP) has acquired an additional interest in the Bradford and Lewisham Building Schools for the Future (BSF) Project. INPP is committing a further £3.6m to acquire stakes in the six PFI project companies that own the fourteen schools providing education facilities to over 17,000 pupils across Bradford and […]
-
27 Jul 2020 1 min read
RTW Venture’s iTeos holding IPOs at a 1.8x multiple to fund’s investment
RTW Venture Fund (RTW), an investment company focused on identifying assets with high growth potential across the life sciences sector, noted the announcement by portfolio company, iTeos Therapeutics (iTeos), on 23 July of its pricing of a $201.1m IPO and admission to trade on NASDAQ. A clinical-stage biotechnology company – oversubscribed IPO values iTeos at 1.8x RTW’s initial investment […]
-
23 Jul 2020 1 min read
RTW announces second deal of the day
RTW announces second deal of the day – RTW Venture Fund confirms that it participated in a private placement of shares in Milestone Pharmaceuticals (committing $25m). Milestone is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone is advancing Etripamil, its lead investigational product, through Phase 3 clinical […]
-
1 min read
RTW backs Encoded Therapeutics
RTW backs Encoded Therapeutics – In June, RTW Venture Fund participated in a $135m Series D financing round for Encoded Therapeutics, together with other investment firms. Encoded is a US-based privately held preclinical stage biotech company developing precision gene therapies for a broad range of severe genetic disorders. This was RTW’s seventh investment following its […]
-
16 Jun 2020 1 min read
RTW Venture applauds Avidity IPO success
RTW Venture applauds Avidity IPO success – RTW Venture Fund Limited has updated on the IPO of its portfolio company Avidity Biosciences, Inc. on 12 June 2020 on NASDAQ (ticker “RNA”). Avidity is a biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates to treat a wide range of serious rare diseases. A $100 million Series C round in […]
-
12 Jun 2020 1 min read
QuotedData’s morning briefing 12 June 2020
In QuotedData’s morning briefing 12 June 2020, as the UK economy contracts by 20.4% in April: Hipgnosis Songs got permission from its shareholders to make greater use of borrowed money to enhance returns. The limit on borrowing has been lifted from 20% of net assets to 30% of net assets. It is now thinking about issuing […]
-
04 Jun 2020 1 min read
RTW Venture invests in Athira Pharma
RTW Venture invests in Athira Pharma – RTW Venture Fund has confirmed that it participated in an $85 million Series B financing for Athira Pharma. The extent of RTW’s contribution to this financing has not been disclosed. Athira is a privately-held clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function. It […]
-
18 May 2020 1 min read
QuotedData’s morning briefing 18 May 2020
In a trading update, ahead of its annual results (to be published on or around 15 June), Jonathan Maxwell, the CEO of SDCL Energy Efficiency Income (SEIT)’s manager, noted: “In spite of the unprecedented global situation around covid-19, the portfolio continues to perform in line with expectations and deliver cheaper, cleaner and more reliable energy […]
-
27 Apr 2020 2 min read
QuotedData’s morning briefing 27 April 2020
European markets have followed Asia in starting the week on the front foot, reflecting the prospect of further central bank support. Meanwhile, New Zealand’s Prime Minister, Jacinda Ardern said the virus was “currently” eliminated, with new reported cases in single figures over a number of days (as reported by the BBC). Norwegian, has said its fleet […]
Upcoming Events
Videos
In The Press
-
26 Nov 2024 1 min read
Investment trust insider on Trump and healthcare
Investment trust insider on Trump and healthcare – James Carthew: If Trump avoids healthcare pain, now’s a good time to buy Donald Trump’s provocative healthcare appointments have caused uncertainty for drugs developers but the outlook remains positive once the political noise abates. Two weeks ago, I wrote about the potential positive impact of the new […]
-
08 Mar 2024 1 min read
The truly cheap trusts trading on the widest discount relative to their history
By Matteo Anelli, Senior reporter, Trustnet, 07 March 2024: In the investment trusts universe wide discounts are often linked to higher long-term returns – and the data backs up this hypothesis. Since 2018, investing in trusts with a double-digit discount have returned an annualised 13.6% in the following five years, a recent study by the […]
-
20 Nov 2023 1 min read
Investment trust insider on RTW Biotech
Investment trust insider on RTW Biotech – James Carthew: RTW Biotech will succeed with or without Arix I was singing the praises of capital markets days last week. Last Tuesday, I managed to get along to one held by RTW Biotech Opportunities (RTW). The day was planned some time ago, but the timing was great […]
-
28 Feb 2023 1 min read
20 investment trusts cheaper now than during Covid-19 sell-off
by Kyle Caldwell from interactive investor, 28th February 2023: Three years ago was a great opportunity to pick up bargains among investment trusts as the Covid-19 pandemic caused widespread panic and fear… Three years ago is a case in point. In response to the emergence of Covid-19, stock markets fell notably, with the FTSE All-Share […]
-
21 Apr 2022 1 min read
Discover the best and worst performing investment trusts so far in 2022
James Crux, Shares Magazine, 21 April 2022: Rising interest rates since the turn of the year, runaway inflation and Russia’s shocking invasion of Ukraine have shaken the investment kaleidoscope in 2022 and forced many investors to reposition portfolios for an increasingly uncertain world… COMMODITIES TRUSTS IN DEMAND Precipitated by the supply/demand imbalances caused as global […]
-
05 Apr 2022 1 min read
Investment trust insider on biotech – James Carthew: What’s gone wrong with biotechnology?
About a year ago, I wrote an article on biotech and said that I was minded to stick by my biotech and healthcare investments – Biotech Growth (BIOG), Worldwide Healthcare (WWH) and Syncona (SYNC). In retrospect, this doesn’t look like a great idea. Over the past 12 months, BIOG and SYNC’s shares are down by […]
-
15 Aug 2021 1 min read
interactive investor review of Syncona sparks debate
Despite remaining positive on the £1.3bn Syncona investment trust, experts are questioning its place on the interactive investor’s ethical buy list, the ii ACE 40, following the platform’s decision to place it under formal review. Kathleen Gallagher 13 August 2021 • 3 min read In the year to 11 August the trust has lost 16.1%, while […]
-
08 Sep 2020 1 min read
Investment trust insider on new and newish funds
Investment trust insider on new and newish funds – James Carthew: Let’s hope new trusts are more open than recent launches After a long hiatus, the flotation window appears to be opening up. I thought this week I would have a look to see how the last crop of investment company launches – Nippon Active Value […]
-
07 Jul 2020 2 min read
Investment trust insider on RTW
Investment trust insider on RTW – James Carthew: the biotechs behind RTW’s racy rating Last week I got the chance to speak to Roderick Wong, fund manager [editing mistake by Citywire – I actually talked to Alexandra Taracanova and Stephanie Sirota] of RTW Venture Fund (RTW), a life sciences fund that listed on the London Stock […]
